Filing Flows › Integra Lifesciences Holdings (IART) › Guidance & outlook
Integra Lifesciences Holdings (IART) guidance and outlook
Integra Lifesciences Holdings (IART) raised its guidance on Oct 21, 2026: Revenue $1.6B–$1.7B for FY2026; EPS $2.30–$2.40 for FY2026; Revenue $413M–$433M for Q4 2026; Revenue −5.2% for Q4 2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.6B–$1.7B | reaffirmed |
| EPS | FY2026 | $2.30–$2.40 | reaffirmed |
| Revenue | Q4 2026 | $413M–$433M | raised |
| Revenue | Q4 2026 | −5.2% | new |
| Revenue | FY2026 | −0.1% to +1.2% | new |
| Operating cash flow | FY2026 | $190M–$200M | reaffirmed |
From the earnings release filed Oct 21, 2026 (8-K on EDGAR).
Integra Lifesciences Holdings' latest quarter
Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%, net earnings $14.9M, operating cash flow $96.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Integra Lifesciences Holdings raise or lower its guidance?
Integra Lifesciences Holdings (IART) raised its guidance on Oct 21, 2026: Revenue $1.6B–$1.7B for FY2026; EPS $2.30–$2.40 for FY2026; Revenue $413M–$433M for Q4 2026; Revenue −5.2% for Q4 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.